keyword
https://read.qxmd.com/read/37030444/early-results-following-comparison-of-radiofrequency-and-microfoam-ablation-of-large-diameter-truncal-veins-demonstrate-high-closure-rates-and-symptomatic-relief
#1
JOURNAL ARTICLE
Amanda L Chin, Stephanie D Talutis, Peter F Lawrence, Juan Carlos Jimenez
OBJECTIVE: Endovenous closure of truncal veins with a large diameter (LD) (≥8 mm) has been associated with higher risk of post ablation thrombus propagation into the deep venous system. Similar findings after Varithena microfoam ablation (MFA) have not been characterized. The study objective was to analyze outcomes after both radiofrequency ablation (RFA) and MFA and of LD truncal veins. METHODS: A retrospective review of a prospectively maintained database was performed...
July 2023: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://read.qxmd.com/read/36972751/view-vlu-observational-study-of-the-effect-of-varithena-on-wound-healing-in-the-treatment-of-venous-leg-ulcers
#2
JOURNAL ARTICLE
Michael Y Shao, Stuart Harlin, Beverly Chan, KathyLee Santangelo, Eri Fukaya, Julianne Stoughton, Raghu Kolluri
OBJECTIVES: Chronic venous hypertension, triggered by venous reflux and/or obstruction, leads to skin changes and venous leg ulcers. Compression therapy is standard of care, but many wounds remain unhealed. The objectives of this study were to observe the effects of endovenous chemical ablation with commercially available 1% polidocanol injectable microfoam on venous leg ulcer healing and recurrence rates. METHODS: The VIEW VLU study was a multicenter, open-label, Phase 4 registry of patients with active venous leg ulcers resulting from venous insufficiency of the great saphenous vein and/or anterior accessory saphenous vein systems who underwent ablation with 1% polidocanol microfoam...
March 25, 2023: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://read.qxmd.com/read/36592692/prospective-randomized-trial-of-anti-thrombotic-strategies-following-great-saphenous-vein-ablation-using-injectable-polidocanol-endovenous-microfoam-varithena%C3%A2
#3
JOURNAL ARTICLE
Jady Yang, Steve Chung, Sanjay Srivatsa
OBJECTIVE: Post-ablation deep vein thrombosis (DVT) represents a potentially serious complication following Varithena™ polidocanol endovenous microfoam (PEM) ablation. The following primary outcomes were assessed: Whether (1) adjunctive Apixaban anticoagulation or (2) mechanical DVS saline flushing could reduce SFJ thrombus extension (PASTE) and/or DVT compared with compression alone, following GSV PEM ablation. METHODS: Varithena™ 1% PEM ablation patients were randomized to: 1) SFJ compression, 2) Compression and DVS saline flushing, or 3) Compression, DVS saline flushing, and 5 days post-procedural 5mg BID oral Apixaban anticoagulation...
December 30, 2022: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://read.qxmd.com/read/33248297/adjunctive-techniques-to-minimize-thrombotic-complications-following-microfoam-sclerotherapy-of-saphenous-trunks-and-tributaries
#4
JOURNAL ARTICLE
Juan Carlos Jimenez, Peter F Lawrence, Karen Woo, Tristen T Chun, Steven M Farley, David A Rigberg, Donald T Baril, Brian G Derubertis
OBJECTIVE: Thrombus extension into the deep venous system following superficial vein chemical ablation with Varithena polidocanol microfoam has been reported. The objective of this study was to assess the effect of intraoperative improved techniques during treatment for patients with symptomatic varicose veins and their impact on extension of thrombus into deep veins. METHODS: A retrospective review of a prospectively maintained database was performed. All patients who underwent endovenous chemical ablation with polidocanol microfoam (Varithena, Boston Scientific, Marlborough, Mass) for symptomatic superficial axial and tributary vein reflux were identified...
July 2021: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://read.qxmd.com/read/31285447/in-vitro-and-ex-vivo-evaluation-of-the-biological-performance-of-sclerosing-foams
#5
JOURNAL ARTICLE
Elisabetta Bottaro, Jemma A J Paterson, Luciano Quercia, Xunli Zhang, Martyn Hill, Venisha A Patel, Stephen A Jones, Andrew L Lewis, Timothy M Millar, Dario Carugo
Since the first reports on foam sclerotherapy, multiple studies have been conducted to determine the physical properties and behavior of foams, but relatively little is known about their biological effects on the endothelial cells lining the vessel wall. Moreover, a systematic comparison of the biological performance of foams produced with different methods has not been carried out yet. Herein, a 2D in vitro method was developed to compare efficacy of commercially available polidocanol injectable foam (PEM, Varithena) and physician-compounded foams (PCFs)...
July 8, 2019: Scientific Reports
https://read.qxmd.com/read/29772321/use-of-polidocanol-endovenous-microfoam-to-improve-hemodynamics-and-symptomology-in-patients-with-challenging-clinical-presentations-a-case-series
#6
JOURNAL ARTICLE
Paul E Davis, John Phillips, Raghu Kolluri
BACKGROUND: Chronic venous insufficiency (CVI) is a widely prevalent condition. Saphenous venous reflux is the most common underlying pathology that leads to CVI. Endovenous thermal ablations (ETA) are the current gold standard. However, some patients present with some unique challenges making ETA less ideal. Nonthermal nontumescent therapies could be considered as alternative therapy in these patients. METHODS: We performed a retrospective review of treatment effects with United States Food and Drug Administration-approved polidocanol endovenous microfoam (PEM; Varithena® 1%) on venous symptomology in 10 (n = 10) C3-C6 patients with CVI and concomitant complex disease/pathology that limited the use of ETA...
October 2018: Annals of Vascular Surgery
https://read.qxmd.com/read/28166694/novel-developments-in-foam-sclerotherapy-focus-on-varithena%C3%A2-polidocanol-endovenous-microfoam-in-the-management-of-varicose-veins
#7
REVIEW
Phoebe Star, David E Connor, Kurosh Parsi
Scope Varithena® is a recently approved commercially available drug/delivery unit that produces foam using 1% polidocanol for the management of varicose veins. The purpose of this review is to examine the benefits of foam sclerotherapy, features of the ideal foam sclerosant and the strengths and limitations of Varithena® in the context of current foam sclerotherapy practices. Method Electronic databases including PubMed, Medline (Ovid) SP as well as trial registries and product information sheets were searched using the keywords, 'Varithena', 'Varisolve', 'polidocanol endovenous microfoam', 'polidocanol' and/or 'foam sclerotherapy/sclerosant'...
April 2018: Phlebology
https://read.qxmd.com/read/27013511/a-multicenter-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-varithena%C3%A2-polidocanol-endovenous-microfoam-1-for-symptomatic-visible-varicose-veins-with-saphenofemoral-junction-incompetence
#8
RANDOMIZED CONTROLLED TRIAL
Kathleen Gibson, Lowell Kabnick
Objectives A randomized, placebo-controlled, multicenter study was conducted to evaluate the safety and efficacy of polidocanol endovenous microfoam (1%, Varithena® [polidocanol injectable foam], BTG International Ltd.). Methods Patients (n = 77) with symptomatic, visible varicose veins were randomized to treatment with either Varithena 1% or placebo. Results Varithena provided greater mean changes from Baseline in patient-reported assessments of symptoms (e.g., heaviness, achiness, swelling, throbbing, itching [HASTI®] score 30...
April 2017: Phlebology
https://read.qxmd.com/read/26992303/durability-of-treatment-effect-with-polidocanol-endovenous-microfoam-on-varicose-vein-symptoms-and-appearance-vanish-2
#9
RANDOMIZED CONTROLLED TRIAL
Kenneth L Todd, David I Wright
OBJECTIVE: The objectives of this study were to assess the durability of response to treatment with polidocanol endovenous microfoam (Varithena; Provensis Ltd, a BTG International group company) and to assess the long-term safety of the study patients. METHODS: This report presents efficacy and safety data from the day after visit 5/week 8 (the primary end point of the study) through the 1-year study visit. As the approved dose concentration is 1%, this analysis focuses on those patients who were randomized to polidocanol endovenous microfoam 1% at study visit 2...
July 2015: Journal of Vascular Surgery. Venous and Lymphatic Disorders
https://read.qxmd.com/read/26957489/a-multicenter-randomized-placebo-controlled-trial-of-endovenous-thermal-ablation-with-or-without-polidocanol-endovenous-microfoam-treatment-in-patients-with-great-saphenous-vein-incompetence-and-visible-varicosities
#10
RANDOMIZED CONTROLLED TRIAL
Michael Vasquez, Antonios P Gasparis
Objectives * Varithena 017 Investigator Group: Michael Vasquez, MD, Venous Institute of Buffalo, Amherst, NY; Antonios Gasparis, MD, Stony Brook University Medical Center, Stony Brook, NY; Kathleen Gibson, MD, Lake Washington Vascular, Bellevue, WA; James Theodore King, MD, Vein Clinics of America, Oakbrook Terrace, IL; Nick Morrison, MD, Morrison Vein Institute, Scottsdale, AZ; Girish Munavalli, MD, Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC; Eulogio J. Sanchez, MD, Batey Cardiovascular Center, Bradenton, FL...
May 2017: Phlebology
https://read.qxmd.com/read/26449448/the-role-of-clinically-relevant-parameters-on-the-cohesiveness-of-sclerosing-foams-in-a-biomimetic-vein-model
#11
JOURNAL ARTICLE
Dario Carugo, Dyan N Ankrett, Vincent O'Byrne, David D I Wright, Andrew L Lewis, Martyn Hill, Xunli Zhang
We have recently reported on the development of a biomimetic vein model to measure the performance of sclerosing foams. In this study we employed the model to compare the commercially-available Varithena(®) (polidocanol injectable foam) 1% varicose vein treatment (referred to as polidocanol endovenous microfoam, or PEM) with physician compounded foams (PCFs) made using different foam generation methods (Double Syringe System and Tessari methods) and different foam formulations [liquid to gas ratios of 1:3 or 1:7; gas mixtures composed of 100% CO2, various CO2:O2 mixtures and room air (RA)]...
November 2015: Journal of Materials Science. Materials in Medicine
https://read.qxmd.com/read/26384639/treatment-of-truncal-incompetence-and-varicose-veins-with-a-single-administration-of-a-new-polidocanol-endovenous-microfoam-preparation-improves-symptoms-and-appearance
#12
RANDOMIZED CONTROLLED TRIAL
J T King, M O'Byrne, M Vasquez, D Wright
OBJECTIVE: This multicenter, parallel group study was designed to determine if a single administration of ≤15 mL of pharmaceutical-grade polidocanol endovenous microfoam (PEM, now approved in the United States as Varithena [polidocanol injectable foam], BTG International Ltd.) could alleviate symptoms and improve appearance of varicose veins in a typical population of patients with moderate to very severe symptoms of superficial venous incompetence and visible varicosities of the great saphenous vein (GSV) system...
December 2015: European Journal of Vascular and Endovascular Surgery
https://read.qxmd.com/read/26218793/polidocanol-varithena-for-varicose-veins
#13
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 3, 2015: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/26036246/benefits-of-polidocanol-endovenous-microfoam-varithena%C3%A2-compared-with-physician-compounded-foams
#14
JOURNAL ARTICLE
Dario Carugo, Dyan N Ankrett, Xuefeng Zhao, Xunli Zhang, Martyn Hill, Vincent O'Byrne, James Hoad, Mehreen Arif, David D I Wright, Andrew L Lewis
OBJECTIVE: To compare foam bubble size and bubble size distribution, stability, and degradation rate of commercially available polidocanol endovenous microfoam (Varithena®) and physician-compounded foams using a number of laboratory tests. METHODS: Foam properties of polidocanol endovenous microfoam and physician-compounded foams were measured and compared using a glass-plate method and a Sympatec QICPIC image analysis method to measure bubble size and bubble size distribution, Turbiscan™ LAB for foam half time and drainage and a novel biomimetic vein model to measure foam stability...
May 2016: Phlebology
https://read.qxmd.com/read/24843085/endovenous-chemical-and-physical-treatments-for-varices-what-s-new
#15
REVIEW
Jean-Jérôme Guex
The constant evolution of endo-venous ablative techniques for varicose veins arises from the need for: better patient's comfort, reduced incidence of side effects, better results at short-, mid- and long-term follow-up, as well as reduction of operating time and technical simplicity. All these goals have been aimed at but so far no new technology has been able to achieve them all or to demonstrate it, furthermore the increase of price must be compensated by a considerable improvement of results and a serious reduction of side effects to be incrementally cost effective...
May 2014: Phlebology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.